Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2012, Article ID 536426, 8 pages
http://dx.doi.org/10.1155/2012/536426
Research Article

The Effect of the Thioether-Bridged, Stabilized Angiotensin-(1–7) Analogue Cyclic Ang-(1–7) on Cardiac Remodeling and Endothelial Function in Rats with Myocardial Infarction

1Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
2LanthioPep, Nijenborgh 4, 9747 AG Groningen, The Netherlands
3BiOMaDe Technology Foundation, Groningen, The Netherlands
4Department of Pharmacology and Therapy, College of Health Sciences, University of Ilorin, Ilorin, Nigeria

Received 21 July 2011; Accepted 11 August 2011

Academic Editor: Anderson J. Ferreira

Copyright © 2012 Matej Durik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Iusuf, R. H. Henning, W. H. van Gilst, and A. J. M. Roks, “Angiotensin-(1–7): pharmacological properties and pharmacotherapeutic perspectives,” European Journal of Pharmacology, vol. 585, no. 2-3, pp. 303–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. Ferreira, R. A. S. Santos, C. N. Bradford et al., “Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases,” Hypertension, vol. 55, no. 2, pp. 207–213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. S. Santos, A. C. Simoes e Silva, C. Maric et al., “Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8258–8263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. E. Loot, A. J. M. Roks, R. H. Henning et al., “Angiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in rats,” Circulation, vol. 105, no. 13, pp. 1548–1550, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Wang, C. Qian, A. J. M. Roks et al., “Circulating rather than cardiac angiotensin-(1–7) stimulates cardioprotection after myocardial infarction,” Circulation, vol. 3, no. 2, pp. 286–293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Kucharewicz, R. Pawlak, T. Matys, D. Pawlak, and W. Buczko, “Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1–7),” Hypertension, vol. 40, no. 5, pp. 774–779, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. W. O. Sampaio, R. A. S. Dos Santos, R. Faria-Silva, L. T. Da Mata Machado, E. L. Schiffrin, and R. M. Touyz, “Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways,” Hypertension, vol. 49, no. 1, pp. 185–192, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. W. O. Sampaio, C. H. De Castro, R. A. S. Santos, E. L. Schiffrin, and R. M. Touyz, “Angiotensin-(1–7) counterregulates angiotensin II signaling in human endothelial cells,” Hypertension, vol. 50, no. 6, pp. 1093–1098, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Qian, R. G. Schoemaker, W. H. van Gilst, and A. J. M. Roks, “The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function,” Clinical Science, vol. 116, no. 4, pp. 301–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. L. D. Kluskens, S. A. Nelemans, R. Rink et al., “Angiotensin-(1–7) with thioether bridge: an angiotensin- converting enzyme-resistant, potent angiotensin-(1–7) analog,” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 3, pp. 849–855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Langeveld, W. H. Van Gilst, R. A. Tio, F. Zijlstra, and A. J. M. Roks, “Angiotensin-(1–7) attenuates neointimal formation after stent implantation in the rat,” Hypertension, vol. 45, no. 1, pp. 138–141, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Iwata, R. T. Cowling, D. Gurantz et al., “Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects,” American Journal of Physiology, vol. 289, no. 6, pp. H2356–H2363, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. L. Grobe, A. P. Mecca, M. Lingis et al., “Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7),” American Journal of Physiology, vol. 292, no. 2, pp. H736–H742, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Durand, G. Raffai, B. D. Weinberg, and J. H. Lombard, “Angiotensin-(1–7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries,” American Journal of Physiology, vol. 299, no. 4, pp. H1024–H1033, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Tesanovic, A. Vinh, T. A. Gaspari, D. Casley, and R. E. Widdop, “Vasoprotective and atheroprotective effects of angiotensin (1–7) in apolipoprotein E-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 8, pp. 1606–1613, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Rentzsch, M. Todiras, R. Iliescu et al., “Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function,” Hypertension, vol. 52, no. 5, pp. 967–973, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. A. Rabelo, P. Xu, M. Todiras et al., “Ablation of angiotensin (1–7) receptor Mas in C57Bl/6 mice causes endothelial dysfunction,” Journal of the American Society of Hypertension, vol. 2, no. 6, pp. 418–424, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Peiró, S. Vallejo, F. Gembardt et al., “Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function,” Journal of Hypertension, vol. 25, no. 12, pp. 2421–2425, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Xu, A. C. Costa-Goncalves, M. Todiras et al., “Endothelial dysfunction and elevated blood pressure in Mas gene-deleted mice,” Hypertension, vol. 51, no. 2, pp. 574–580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. B. E. Langeveld, R. H. Henning, B. J. G. L. De Smet et al., “Rescue of arterial function by angiotensin-(1–7): towards improvement of endothelial function by drug-eluting stents,” Netherlands Heart Journal, vol. 16, no. 9, pp. 293–298, 2008. View at Google Scholar · View at Scopus
  21. R. Faria-Silva, F. V. Duarte, and R. A. Santos, “Short-term angiotensin(1–7) receptor MAS stimulation improves endothelial function in normotensive rats,” Hypertension, vol. 46, no. 4, pp. 948–952, 2005. View at Google Scholar · View at Scopus
  22. L. de Vries, C. E. Reitzema-Klein, A. Meter-Arkema et al., “Oral and pulmonary delivery of thioether-bridged angiotensin-(1–7),” Peptides, vol. 31, no. 5, pp. 893–898, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Iusuf, R. H. Henning, W. H. van Gilst, and A. J. M. Roks, “Angiotensin-(1–7): pharmacological properties and pharmacotherapeutic perspectives,” European Journal of Pharmacology, vol. 585, no. 2-3, pp. 303–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. F. D. Marques, A. J. Ferreira, R. Sinisterra et al., “An oral formulation of angiotensin-(1–7) produces cardioprotective effects in infarcted and isoproterenol-treated rats,” Hypertension, vol. 57, no. 3, pp. 477–483, 2011. View at Publisher · View at Google Scholar
  25. S. Q. Savergnini, M. Beiman, R. Q. Lautner et al., “Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the mas receptor,” Hypertension, vol. 56, no. 1, pp. 112–120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. J. Ferreira, V. Shenoy, Y. Yamazato et al., “Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 11, pp. 1048–1054, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. J. Ferreira, V. Shenoy, Y. Qi et al., “Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases,” Experimental Physiology, vol. 96, no. 3, pp. 287–294, 2011. View at Publisher · View at Google Scholar